Alto Neuroscience, Inc. (ANRO) Form 8-K — May 28, 2026

$ANROForm 8-KItems 5.02Filed May 28, 2026, 8:18 AM ET0001999480-26-000016Original filing

Alto Neuroscience appointed Andrew Miller, Ph.D., to its Board of Directors effective May 27, 2026, filling a vacancy created by a prior board expansion. Dr. Miller brings extensive biotech leadership experience, having founded Karuna Therapeutics and served as its President of R&D before its acquisition by Bristol Myers Squibb. Dr.

Key figures

Annual option shares: 24100
Initial option shares: 48200
Committee retainer usd: 5000
Annual cash retainer usd: 40000
Annual option max value usd: 200000
Initial option max value usd: 400000

Price after filing

1 day: 0.0%7 days: -0.9%30 days: +25.1%

Close on the filing date to close N calendar days later (from $20.22). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.